Loading data for MCK — first visit, this takes a few seconds.

McKesson Corporation (MCK)

NYSE: MCK · リアルタイム株価 · USD

891.68

+2.56 (0.29%)

終値時点： Sep 09, 2026, 3:59 PM

891.68

+0.00%

時間外: 6:05 PM

アラート

Alert

株価、主要な数字、最新ニュースをひとまとめにしたページです。

0.29% (1D)

買気配	859.06
時価総額	104B
売上高（TTM）	411B
純利益（TTM）	4.59B
	0.31
	37.25
	23.94
	17.67
PBR（TTM）	-24.39
PSR（TTM）	0.25
決算発表日	Nov 4, 2026

売気配	892.9
出来高	935,711
平均出来高（20日）	1,035,465
始値	889.25
前日終値	889.12
当日レンジ	881.12 - 897.46
52週レンジ	687.68 - 999.00
アナリスト	n/a
目標株価	n/a
配当	$3.76 (0.42%)
権利落ち日	Sep 1, 2026

MCKについて

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, l...

[続きを読む]

業種 Medical Distribution

セクター Healthcare

IPO日 Nov 10, 1994

従業員数 41,600

上場取引所 NYSE

ティッカー MCK

ウェブサイト https://www.mckesson.com

企業情報の全文

業績

2026年のMcKessonの売上高は403.43Bで、前年の359.05Bから12.36%の増加でした。利益は4.76Bで、44.52%の増加でした。

財務諸表

決算サプライズ

McKessonはAug 5, 2026に四半期決算を発表しました：

売上高は $105.38B で、予想を下回りました $0, うち 7.72% の前年比増加にあたります.
EPSは 9.93 で、予想を上回りました 0.39, うち 20.22% の前年比増加にあたります.

次回決算発表

McKesson Corporationの決算発表予定日は Nov 4, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

株価が動いた理由

ニュース

10時間前 · Zacks

McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

1日前 · StockStory

3 Market-Beating Stocks for Long-Term Investors

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legend...

1日前 · MarketBeat

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo...

2日前 · Zacks

Here's How CVS Is Focusing on Aetna's Profitability Turnaround

CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.

3日前 · Insider Monkey

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen it...

2ページ中1ページ

McKesson Corporation (MCK)